e 4031 has been researched along with Torsade de Pointes in 19 studies
E 4031: class III anti-arrhythmia agent; structure given in UD
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS)." | 7.73 | Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. ( Aiba, T; Ding, WG; Horie, M; Inagaki, M; Matsuura, H; Miyoshi, S; Noda, T; Shimizu, W; Sunagawa, K; Toyoda, F; Zankov, DP, 2005) |
| "We examined the cellular and ionic mechanism for QT prolongation and subsequent Torsade de Pointes (TdP) and the effect of verapamil under conditions mimicking KCNQ1 (I(Ks) gene) defect linked to acquired long QT syndrome (LQTS)." | 3.73 | Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. ( Aiba, T; Ding, WG; Horie, M; Inagaki, M; Matsuura, H; Miyoshi, S; Noda, T; Shimizu, W; Sunagawa, K; Toyoda, F; Zankov, DP, 2005) |
| "We analyzed torsadogenic and pharmacokinetic profile of E-4031 using chronic atrioventricular block dogs." | 1.48 | Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects. ( Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Naito, AT; Sugiyama, A, 2018) |
| "Arrhythmic outcome was defined as Torsade de Pointes (TdP) in the animal models and early afterdepolarizations (EADs) in the cell models." | 1.38 | Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes. ( Beekman, JD; de Boer, TP; Duker, G; Houtman, MJ; Jonsson, MK; Nalos, L; Peschar, M; Rook, MB; Sartipy, P; Thomsen, MB; van der Heyden, MA; van der Nagel, R; van Veen, TA; Varkevisser, R; Vos, MA, 2012) |
| "Fluoxetine (Prozac) was more potent at blocking hERG 1a/1b than 1a channels, yielding a corresponding reduction in the safety margin." | 1.37 | hERG subunit composition determines differential drug sensitivity. ( Abi-Gerges, N; Holkham, H; Jones, EM; Pollard, CE; Robertson, GA; Valentin, JP, 2011) |
| "However, the cycle length of the arrhythmia with quinidine was longer than that for control ([mean +/- SEM] 194 +/- 12 vs." | 1.30 | Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart. ( Asano, Y; Baxter, WT; Davidenko, JM; Gray, RA; Jalife, J, 1997) |
| "Tamoxifen is an antiestrogen drug commonly used to treat breast cancer and has been shown to cause prolongation of the electrocardiographic QT interval in humans." | 1.30 | The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. ( Ebert, SN; Katchman, A; Liu, XK; Woosley, RL, 1998) |
| " Agents were compared over dosage ranges that produced maximal increases in QTc interval and monophasic action potential duration (MAPD)." | 1.29 | Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. ( Brunden, MN; Buchanan, LV; Gibson, JK; Kabell, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wiśniowska, B | 1 |
| Mendyk, A | 1 |
| Fijorek, K | 1 |
| Glinka, A | 1 |
| Polak, S | 1 |
| Goto, A | 1 |
| Izumi-Nakaseko, H | 1 |
| Hagiwara-Nagasawa, M | 1 |
| Chiba, K | 1 |
| Ando, K | 1 |
| Naito, AT | 1 |
| Sugiyama, A | 2 |
| Wang, WL | 1 |
| Zhang, SS | 1 |
| Deng, J | 1 |
| Zhao, JY | 1 |
| Zhao, CQ | 1 |
| Lin, L | 1 |
| Zhang, CT | 1 |
| Lv, JG | 1 |
| Yamamoto, W | 1 |
| Asakura, K | 1 |
| Ando, H | 1 |
| Taniguchi, T | 1 |
| Ojima, A | 1 |
| Uda, T | 1 |
| Osada, T | 1 |
| Hayashi, S | 1 |
| Kasai, C | 1 |
| Miyamoto, N | 1 |
| Tashibu, H | 1 |
| Yoshinaga, T | 1 |
| Yamazaki, D | 1 |
| Kanda, Y | 1 |
| Sawada, K | 1 |
| Sekino, Y | 1 |
| Wu, L | 2 |
| Rajamani, S | 1 |
| Li, H | 2 |
| January, CT | 1 |
| Shryock, JC | 2 |
| Belardinelli, L | 2 |
| Abi-Gerges, N | 1 |
| Holkham, H | 1 |
| Jones, EM | 1 |
| Pollard, CE | 1 |
| Valentin, JP | 1 |
| Robertson, GA | 1 |
| Ma, J | 1 |
| Wang, C | 1 |
| Grandi, E | 1 |
| Zhang, P | 1 |
| Luo, A | 1 |
| Bers, DM | 1 |
| Nalos, L | 1 |
| Varkevisser, R | 1 |
| Jonsson, MK | 1 |
| Houtman, MJ | 1 |
| Beekman, JD | 1 |
| van der Nagel, R | 1 |
| Thomsen, MB | 1 |
| Duker, G | 1 |
| Sartipy, P | 1 |
| de Boer, TP | 1 |
| Peschar, M | 1 |
| Rook, MB | 1 |
| van Veen, TA | 1 |
| van der Heyden, MA | 1 |
| Vos, MA | 1 |
| Said, TH | 1 |
| Wilson, LD | 1 |
| Jeyaraj, D | 1 |
| Fossa, AA | 1 |
| Rosenbaum, DS | 1 |
| Choi, BR | 1 |
| Burton, F | 1 |
| Salama, G | 1 |
| Fish, JM | 1 |
| Di Diego, JM | 1 |
| Nesterenko, V | 1 |
| Antzelevitch, C | 2 |
| Aiba, T | 1 |
| Shimizu, W | 1 |
| Inagaki, M | 1 |
| Noda, T | 1 |
| Miyoshi, S | 1 |
| Ding, WG | 1 |
| Zankov, DP | 1 |
| Toyoda, F | 1 |
| Matsuura, H | 1 |
| Horie, M | 1 |
| Sunagawa, K | 1 |
| Michael, G | 2 |
| Dempster, J | 1 |
| Kane, KA | 2 |
| Coker, SJ | 2 |
| Buchanan, LV | 1 |
| Kabell, G | 1 |
| Brunden, MN | 1 |
| Gibson, JK | 1 |
| Asano, Y | 1 |
| Davidenko, JM | 1 |
| Baxter, WT | 1 |
| Gray, RA | 1 |
| Jalife, J | 1 |
| Burashnikov, A | 1 |
| Liu, XK | 1 |
| Katchman, A | 1 |
| Ebert, SN | 1 |
| Woosley, RL | 1 |
| Miyashita, T | 1 |
| Kubota, I | 1 |
| Yamaki, M | 1 |
| Watanabe, T | 1 |
| Yamauchi, S | 1 |
| Tomoike, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
19 other studies available for e 4031 and Torsade de Pointes
| Article | Year |
|---|---|
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computationa | 2012 |
Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects.
Topics: Animals; Anti-Arrhythmia Agents; Atrioventricular Block; Chronic Disease; Dogs; Dose-Response Relati | 2018 |
KN-93, A CaMKII inhibitor, suppresses ventricular arrhythmia induced by LQT2 without decreasing TDR.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzylamines; Calcium-Calm | 2013 |
Electrophysiological Characteristics of Human iPSC-Derived Cardiomyocytes for the Assessment of Drug-Induced Proarrhythmic Potential.
Topics: Cells, Cultured; Chromans; Cisapride; Electrophysiological Phenomena; Heart Rate; Humans; Induced Pl | 2016 |
Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Topics: 4-Aminopyridine; Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Barium Compounds; | 2009 |
hERG subunit composition determines differential drug sensitivity.
Topics: Action Potentials; Arrhythmias, Cardiac; Cell Line, Transformed; Drug Evaluation, Preclinical; Ether | 2011 |
Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization.
Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Bradycardia; Disease Models, Anima | 2011 |
Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Aza Compounds; Cell Line; Disease Models, Animal | 2012 |
Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia.
Topics: Action Potentials; Animals; Bepridil; Dogs; Dose-Response Relationship, Drug; Electrocardiography; E | 2012 |
Cytosolic Ca2+ triggers early afterdepolarizations and Torsade de Pointes in rabbit hearts with type 2 long QT syndrome.
Topics: Animals; Anti-Arrhythmia Agents; Artifacts; Calcium; Calcium Signaling; Cryosurgery; Cytosol; Female | 2002 |
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Cisapride; Computer | 2004 |
Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Cats; Chromans; Heart; | 2005 |
Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation.
Topics: Action Potentials; Animals; Chromans; Cnidarian Venoms; Delayed Rectifier Potassium Channels; Dose-R | 2007 |
Adrenaline reveals the torsadogenic effect of combined blockade of potassium channels in anaesthetized guinea pigs.
Topics: Action Potentials; Animals; Chromans; Delayed Rectifier Potassium Channels; Dose-Response Relationsh | 2008 |
Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Electrocardiography; Heart Conduction System; Heart | 1993 |
Optical mapping of drug-induced polymorphic arrhythmias and torsade de pointes in the isolated rabbit heart.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Heart | 1997 |
Acceleration-induced action potential prolongation and early afterdepolarizations.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Calcium Channel Blockers; Disease Models, Animal | 1998 |
The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes.
Topics: Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Estrogen Antagonists; Heart Ventr | 1998 |
4-aminopyridine inhibits the occurrence of ventricular fibrillation but not ventricular tachycardia in the reperfused, P6olated rat heart.
Topics: 4-Aminopyridine; Animals; Anti-Arrhythmia Agents; Blood Flow Velocity; Glyburide; Heart; Heart Rate; | 2000 |